Compare MNTK & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | RCEL |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.0M | 171.5M |
| IPO Year | 2020 | N/A |
| Metric | MNTK | RCEL |
|---|---|---|
| Price | $1.42 | $4.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.80 | ★ $7.88 |
| AVG Volume (30 Days) | ★ 250.7K | 209.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $176,382,000.00 | N/A |
| Revenue This Year | $18.55 | $17.17 |
| Revenue Next Year | $12.68 | $49.82 |
| P/E Ratio | $147.00 | ★ N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.07 | $3.22 |
| 52 Week High | $2.78 | $9.85 |
| Indicator | MNTK | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 49.09 |
| Support Level | $1.37 | $4.37 |
| Resistance Level | $1.58 | $4.57 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 58.54 | 19.25 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.